Device Trial Radar · NCT02747264
eRAPID Feasibility Pilot Study in Pelvic Radiotherapy
Last checked: Nov 19, 2026Latest source record: Apr 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
167
Actual
Start
Dec 1, 2016
Primary completion
Jun 1, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Leeds Teaching Hospitals NHS Trust; The Christie NHS Foundation Trust
- First posted
- Apr 21, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) programme is to determine whether eRAPID (an online system for patients to self-report symptoms and side effects) can enhance patient care and improve the safe delivery of cancer treatments. The investigators hypothesise that patient symptoms will be detected earlier with more timely admissions and a reduction in overall hospital contacts. It is predicted that staff will save time recording symptoms and side effects and will be able to focus attention during clinical contacts on more severe side effects. eRAPID is a cost-effective approach to supporting patient self-management and reducing hospital/General Practitioner (GP)/community contacts. The majority of the research will be run with systemic patients. This particular part of the research is a feasibility study in radiotherapy (RT) patients to test the platform in a different patient group.
Conditions
- Cancer
Interventions
eRAPIDDevice
eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with self-reported outcome data at each time-pointTime frame: 6 months
- Proportion of missing data in patient outcome questionnairesTime frame: 6 months
- Appropriateness of patient outcome questionnaires by assessing ceiling and floor effects ( quality of life questionnaire)Time frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Christie Hospital
Manchester, Greater Manchester, United Kingdom
St James University Hospital
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.